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Abstract : Peritonea1 dissemination is a specia1 condition of gastric canc巴rmetastasis， 
which worsens the qua1ity of patients' lives and is often difficult to control. In this study， 
we describe the basic features of the peritonea1 dissemination of gastric cancer. Some 
mo1ecu1ar events are associated with the peritonea1 dissemination， including c-met gene 
amplification， chromosome 7q de1etion， and Reg IV overexpression. Especially， Reg IV 
overexpression enhances the antiapoptotic property of gastric cancer cels. In contrast， 
activation of PP ARg inhibits the peritonea1 dissemination by the pro【apoptoticeffect 
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INTRODUCTION 
Gastric cancer is a 1eading cause of cancer death in the world， and the second most 
common cause of cancer death in Japan1， 2). One fifth of gastric cancer patients showed 
peritonea1 metastasis and/or 1iver metastasis at the operation3) and 30% of patients who died 
from gastric cancer suffered from peritonea1 metastasis4). Peritonea1 metastasis 四 uses
termina1 stage of advanced gastric cancer， and diminishes quality of patients' life by 
intestina1 obstruction， ascites， and ma1nutrition. Contro1 of peritonea1 metastasis is expected 
to make the qua1ity of patients' 1ife better5，6). To understand the mechanism of the peritonea1 
metastasis of gastric cancer is essentia1 for treatment of the condition 
The mo1ecu1ar mechanism of peritonea1 metastasis is an ongoing assignment of cancer 
research. We have identified 10ss of heterozygosity of chromosome 7q invo1ving 7q35 10cus 
as a peritonea1 metastasis-associated event in gastric cancer7). Overexpression of angiogenic 
factors， such as vascu1ar endothe1ia1 growth factor (VEGF) and interleukin (IL)-8， is 
associated with peritoneal metastasis formation and the ascites production in ovarian 
cancerS). Truncated form of fibrob1ast growth factor/keratinocyte growth factor receptor 2 
IIIb (K-sam) and c】metshow gene amp1ification and/or overexpression in scirrhous type 
gastric cancer， which frequent1y produces peritonea1 metastasis9-!l). A gene 巴xpresslOn
profiling shows alteration of severa1 gene expressions in peritonea1 metastasis of scirrhous 
type gastric cancer， such as up-regu1ation of trefoi1 factor 1，α悶1-antitrypsin，and ga1ectin 4， 
and down戸regu1ationof cytidine deaminase12). Cell-to同cel adhesion between cancer cells and 
peritonea1 mesothelia1 cells is thought to be an initia1 step of peritonea1 metastasis. 
Expressions of CD44， s1 integrin， intercellu1ar adhesion mo1ecu1e-1 p1ay a ro1e in cancer cel 
adhesion to mesothe1ia1 cells13-14). The importance of surviva1 factors in periton四 1metastasis 
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formation is emphasized in many reports; RUNX3， survivin， nuclear factor KB， Bcl-2/Bag are 
associated with peritoneal metastasisI5.18). 
Cサnet
The scirrhous type gastric cancer， which frequently produces peritoneal metastasis， 
shows the gene amplification and over巴xpressionof c-met oncogene9， 10)， 
A variety of human cancers express multi-autocrine loops of growth factor/receptor 
system such as EGF， TGF-αand TGF-β， which evidently play a crucial role in tumor 
progressionl9， 20). In gastric carcinomas， many growth factors are frequently overexpressed 
without gene amplification， while growth factor receptor type genes such as ERBB (EGF 
receptor)， ERBB221， 23)and K-sam (FGF receptor)22) are often amplified. The amplification of 
the receptor genes closely correlates with tumor metastasis23). 
An oncogene， met， was initial1y identified in NIH3T3 cel1s transfected with DNA from 
human osteosarcoma cel line (HOS) transformed with N-methyl-N三nitro-N-nitrosoguanidine
(MNNG) 24，お). Subsequent analyses on the proto-form of this gene revealed that 4.2kb of c-met 
cDNA encoded a receptor type tyrosine kinase with a molecular mass of 145KDa26， 27)， c-met 
product is revealed to be a hepatocyte growth factor (HGF) receptor consisting of α血 andβ-
subunits28，29). These subunits are linked by two disulfide bonds to make an insulin receptor-
like structure30，31). Moreover， HGF has been found to be identical with scatter factor or lung 
fibroblast-deriv巴dmitogen3234). 
We examined the amplificョtionof the c-met gene in human esophageal， gastric and 
colorectal cancers9). Six (55%) of the 11 gastric cancer cel lines and 15 (23%) of the 64 
advanced gastric cancers show the ひmetgene amplification， Among them， c-met amplification 
is detected in 5 gastric cancer cel lines， derived from scirrhous gastric cancer and in 5 (38 %) 
of 13 scirrhous gastric cancer. Scirrhous type stomach cancer corresponds to diffusely 
infiltrating carcinoma or Borrmann's typ巴 IVcarcinoma of the stomach showing vast fibrous 
stroma with rapid and extensive growth. Previous studies have shown the specific gen巴tic
features in scirrhous carcinoma. K】samgene amplification preferentially occurs in this type of 
stomach cancer2). Simultaneous overexpression of PDGF and PDGFR mRNA is also detected 
in stomach cancers associated with plentiful fibrous stroma35). TGF一βandbasic FGF are also 
overexpressed in scirrhous type stomach carcinomas36， 37). Since c-met product is the receptor 
protein for HGF 28，田)， gastric cancer cells with c-met amplification should be respo 
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chromosome 7 without major rearrangement. Amplification of the c-met gene is found in one 
of paired alleles in al the cases by southern blot analysis91目 Anotherallele was not amplified 
or deleted. It had been reported that GTL-16 gastric carcinoma cel line with the c凶metgene 
amplification31 has an amplicon including the ひmetgene region without rearrangement nor 
mutation411 • 
Patients of gastric cancer with c目metamplification show significantly advanced tumor 
stage and poorer prognosis than those without the amplification. Conversely， no 
amplification is detected in any of the esophageal and colorectal cancer cel lines as well as 
carcinoma tissues except one colonic cancer. As to clinical features， c-met amplification was 
closely related to tumor progression. That is， advanced gastric carcinomas (stage 11 and 1V) 
shared frequent amplification of c-met， whereas stage 1 gastric carcinomas had no 
amplification. Furthermore， patients with c-met amplification showed significantly worse 
prognosis than those without the amplification. 
These resu1ts overall suggest that amplification of the c-met gene might be implicated in 
carcinogenesis and progression of stomach cancer， especially scirrhous type stomach 
carcinoma. An aberrant shorter transcript of c-Met is also closely associated with 
progression of gastric cancer10I • The normal transcript of the c-met gene is 7.0 kb ; in contrast， 
most gastric cancer cel lines and advanc巴dcancer cases show a 6.0戸kb; in addition to the 7.0-
kb transcript. Expression of this 6.0 kb目transcriptis closely correlat巴dwith tumor stage， 
lymph node metastasis， and depth of tumor invasion41 • Park et al. reported a variant of 
smaller molecular weight of c【Met，which is not confirmed as the protein product of the 6.0 
kb transcript. 
Chromosome 7 q deletion 
The deve10pment and progression of human cancer are considered to occur as resu1ts of 
accumulation of genetic a1teration in a variety of protooncogenes and tumor suppressor 
genes421 • Fr巴quent10ss of heterozygosity (LOH) on chromosomes 1q， 5q and 17p is reported in 
gastric cancer431 • Chromosomes 5q and 17p are well known as the APC and p53 10ci. 
On the 10ng arm of chromosome 7， c-met gene and human hepatocyte growth factor 
(hHGF) gene are located. Sano et al. a1so reported frequent alle1e 10ss (39%) on 7q at D7S22 
10cus in well differentiated gastric cancer431 • We examined the LOH on the 10ng arm of 
chromosome 7 using five p01ymorphic marker probes (D7S95， c-met， D7S63， D7S22， and 
D7S64) in 98 gastric cancers71 • Twenty合 ixcases (32%) of 82 informative cases show LOH on 
7q on at least on巴 10cusof five 10ci. Among five 10ci， LOH at D7S95 10cus is most frequent， 
the incidence being 53% in well differentiated gastric cancers and 33% in poor1y 
differentiated and scirrhous gastric cancers， respective1y. At three 10ci， c】met，D7S63 and 
D7S22， the incidence of LOH is about 30% and 10% in well differentiated and poor1y 
differentiated gastric carcinoma cases， respectively. 1n contrast， LOH at D7S64 is not detected 
in any gastric carcinoma cases. De1etion mapping of 7q reveals that D7S95 locus is the 
essential region of LOH. Two types of gene a1teration， amp1ification and de1etion， rare1y 
occur in a single gene 10cus. Of 98 cases examined， 20 revea1 the c-met gene amp1ification. 
However， al these cases are comp1ete1y different from 26 cases with LOH on 7q. 
Furthermore， amplification is detected on1y by ρmetH and ρmetD probes， whereas no 


















Fig. 1. Expression and g巴nea1teration of c-rnet in gastric cancer 
(a) Overexpression of c-rnet protein in p巴ritonealrnetastasis of gastric cancer. (b) Gene 
arnplification of c-rnet in gastric cancer c巴1lines. MKN-45 cels are derived frorn poorly 
differentiated adenocarcinorna. HSC-39， KATO-III， NKPS， and NT AS cels are derived frorn 
scirrhous type adenocarcinornas with periton巴aldissernination. (c) Loss of heterozygosity 
of chrornosorne 7q in gastric canc巴r.P(一)case 1 isnegative for p巴ritonealdissernination. 
P(+) case 2 ispositive for peritoneal dissernination 
amplification is observed at loci of D7S22， D7S63， D7S95 and D7S64， respectively. Therefore， 
the amplification is considered to be a different event from LOH on 7q and the amplicon may 
be localized in relative short range around ひmetlocus， which is congruent with the literature 
Our examination shows that several cases show wide ranges of the LOH at the 
neighboring 2 to 4 locF). Previous cytogenetic studi巴shave demonstrated th巴 deletionon 7 q 
in gastric cancer4445). The precise mapping of the deletion on 7q has been reported as an 
interstitial deletion of the distal portion of 7q in leukemia cells. The proximal breakpoint of 
the interstitial deletion is determined at 7q2246). In our study， gastric cancers show no 
deletion at D7S64 (7q21) in contrast to frequent LOH at the c】metlocus (7q31). Th巴seresu1ts 
suggest that deletion on 7q in gastric carcinomas might have a similar breakpoint to 
leukemia. However， since the most telomeric locus， D7S22， is deleted in some cases， an 
interstitial deletion of 7q is not common in gastric cancer. 
In our study， 8 cases (62%) of 13 cases with LOH at D7S95 locus belong to stage IV4). 
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Furthermore， 6 cases (75%) of 8 cases with abdominal dissemination show LOH at D7S95. 
Therefore， cases with LOH at D7S95 show significantly worse prognosis than the cases 
without LOH in stage II and IV groups. These findings suggest that the deletion at D7S95 
locus is closely correlated with tumor progression， especially with peritoneal dissemination 
of gastric cancer. In some previous literature， LOH on 7q is also associated with rapid 
progression of leukemia47) or aggressive tumor status and worse prognosis in breast cancer48). 
D7S95 locus may contain candidate suppressor gene for tumor progression. D巴tectionof LOH 
at D7S95 may bring clinical prediction for indicator of high malignancy and may make it 
possible to treat it preventively in advance. 
RegIV 
Reg (regenerating) gene family belongs to the calcium-dependent lectin superfami1y49， 50). Reg 
IV is a new member of the fami1y， which is identified as a gene expressed in the 
gastrointestinal tracts and pancreas51， 52). Human Reg IV gene is located on chromosome 1， 
unlike other Reg family genes， which are located on 2p1253). Reg IV is expressed in Crohn's 
disease and ulcerative colitis51， 54). Reg IV is revealed to be associated with malignant potential 
of colorectal adenocarcinomas， and malignant transformation of colorectal adenomas557). We 
revealed that Reg IValso associated with malignant potentials of salivary gland cancer58) and 
prostate cancer59). Recently， Reg IV is reported to activate epidermal growth factor receptor 
(EGFR)， protein kinase B/ Akt， and activator protein (APト1to accelerate colorectal cancer 
cel survival by increasing Bcl回2，Bcl-XL， and survivin回).Anti-apoptotic property of Reg IV is 
associated with colorectal cancer development61l and drug resistance in gastric cancer62). Reg 
IVexpression is expected to be a marker for high malignant potential of cancer6365). 
We have identified Reg IV as a cancer・-affiliatedexpressed gen巴 byserial analysis of gene 
expression (SAGE) technique， which results were deposited to NCBI SAGE Library in the 
web (http://www.ncbi.nlm.nih.gov/SAGE/). Reg IV protein is immunohistochemically 
detected in 36% of colorectal adenocarcinomas， which is associated with tumor stage， 
whereas Reg IV production is detected in 29% of gastric cancers， which is associated with 
both the intestinal mucin phenotype and n巴uroendocrinedifferentiation but not with tumor 
stage or patient prognosis6). Thus， the role of Reg IV in gastric cancer is stil unclear. 
In our examination， increase of expression and secretion of Reg IV， and levels of BCL-2， 
BCL-XL， survivin， phosphorylated AKT， and phosphorylated EGFR， and decrease of nitric 
oxide】inducedapoptosis are found in Reg IV-transfected gastric cancer cells， whereas those 
are abrogated in the knockdown cells67!. Although nitric oxide (NO) is a strong apoptotic 
inducer68!， the increment of anti-apoptotic factors reduced NO四inducedcytotoxicity in these 
cells. The anti回apoptoticproperty of Reg IV is reported in several studies， which endows 
cancer cells with advantages for survival， progression， and metastasis54，6主62，69)
In mice models， increased number a 
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anti-apoptotic property of cancer cells is emphasized for formation of peritoneal metastasis15-
18) Moreover， remarkable progressions of metastatic tumors worsen survival rates in mic巴
inoculated with the Reg IV-transfected gastric cancer cells than those in mice inoculated with 
the control cells. In contrast， Reg IV knockdown significantly suppresses peritoneal 
metastasis of gastric cells. 
Because Reg IV is a secretory small protein70l， detection of Reg IV protein in ascites might 
be expected as a marker for peritoneal metastasis. In our study， the levels of Reg IV protein 
in peritoneal lavage fluids increase in Reg IV-transfectants inoculated mice， but decrease in 
Reg IV【knockdowncel inoculated mice67). Reg IV protein was detected in al cases with 
macroscopical and cytological peritoneal metastasis. Moreover， al cases with keratin mRNA-
positive ascites showed Reg IV protein in ascites67). Ascites keratin detected by RT】PCRis a 
sensitive marker for scanty cancer cells in ascites in cytologically metastasis-negative cases 
71)目 Thesefindings suggest that ascites Reg IV might be a sensitive marker for peritoneal 
metastasis of gastric cancer. Reg IV is expected to be a marker for early detection of 
peritoneal metastasis and a prognostic marker for gastric cancer. In colon cancer， serum Reg 
IV levels are also associated with liver metastasis at the operation and even with recurrence 
with liver metastasis57). 
PPARγ 
Recently， we reported the importance of activation of peroxisome proliferator-activated 
receptor (PP AR) g in suppression of peritoneal metastasis， which provides tumor growth 
inhibition and apoptosis induction in gastric and colon cancer cells72，73)， As described above， 
anti-apoptotic property is important in establishing peritoneal dissemination， PPARr 
activation induces apoptosis in cancer cells， which is relevant to suppress peritoneal 
dissemina tion 
PPARr is originally identified to induce adipocyte differentiation74). PPARg is a nuc1ear 
hormone receptor superfamily of ligand-activated transcription factors75)， PP ARr is dimerized 
with retinoic X receptor， and binds specific responsive element within promoter DNA 
sequence to regulate gene expression76，77). PPARr initiates transcription of genes associated 
with energy homeostasis， cell growth， and anti-/pro-inflammatory effece5， 7剖) PPARr is 
activated by endog巴nous secreted prostaglandins and fatty acids. 15【deoxy-d(12，14)-
prostaglandin J2 is a strong endogenous ligand of PP ARr. PPARr possesses an anti【
carcinogenic effect in colon cancer. Synthesized PP ARr agonists inc1uding troglitazon have 
been shown to be effective chemopreventive agents in a rat model of carcinogenesis and in 
AOM-induced colon cancer in mice81). Moreover， a decreas巴 inPP ARr expression is associated 
with cancer metastasis82， 83). PPARr play a role in transcriptional regulation of cancer-related 
Fig. 2， Eff巴ctsof Reg 1V transfection on p巴ritonealdissemination of MKN~8 human gastric cancer cels， 
MKN28 cels transfected with control vector (MKN28-RO) or Reg 1V expression vector (MKN28-R2) 
were inoculated into the periton巴alcavity of nude mice. H&E staining showed the large central 
n巴crosisin MKN28-RO tumor but not in MKN28-R2 tumor. Reg IV protein production was found in 
only MKN28-R2 tumor. PCNA labeling indices of MKN28-RO and MKN28-R2 tumors were not 
significantly different. 1n contrast， apoptotic cels wer巴 significant1yincreased in MKN28-RO tumor 
(arrow; apoptotic cels) in comparison with MKN28-R2 t四 nor.
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genes. PPARr downr巴gulatesepithelial growth factor receptor (EGFR)， and upregulates Bax， 
p21Waf戸1，and E-cadherin， which are associated with anti-proliferative， pro目apoptotic，and pro目
differentiation effects84.87). We previously reported that PP ARr induces EGFR and TGF【a
expression by CLA and LA treatment in cancer cel1s72， 731 These alterations col1ectively 
provide an anti-metastatic effect on cancer cel1s. Inhibitory effect of PPARr to cancer 
metastasis is r巴portedin several cancers， such as non-smal1 cel1 lung cancer， colon cancer， 
thyroid cancer， and breast cancer76，87田
We used CLA as a PPARr ligand to inhibit peritoneal metastasis72，同) CLA treatment 
significantly decreases metastatic foci of both cel1s in th巴 peritonealcavity721. Survival rate in 
mice inoculated with gastric cancer cel1s is significantly recovered by CLA treatment. 
Protein production in gastric cancer cel1s treated with CLA shows a decrease in EGFR and 
TGF目aand an increase in Bax. Our results show that CLA inhibits cel1 growth and invasion， 
and induces apoptosis in cancer cel1s. Moreover， CLA inhibited cancer cel1 colonization in the 
peritoneal cavity and decreased death rates of cancer】burdenedmice. We also reported the 
tumor suppressive effect of CLA on established peritoneal tumors using a syngeneic mouse 
peritoneal metastasis modePO). In CLA-treated tumors， proliferating cel1s are decreased， 
whereas apoptotic cel1s are increased. 
Control of peritoneal metastasis is important in improving disease outcome and quality of 
the patient's life. We hope that the recent advances in basic research on the mechanism of 
peritoneal dissemination described above wil1 contribute to establishing tactics to control 
peritoneal dissemination 
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